NxStage Medical (NXTM -2.9%) drops on a downgrade to Hold from Feltl & Co. Feltl considers NxStage shares to be richly priced on an enterprise value/sales basis, given the lack of a near-term catalyst to boost adoption of its home hemiodialysis product. It's also worried competition could arrive sooner than expected.